References
- Adami HO, Kuper H, Andersson SO, et al (2003). Prostate cancer risk and serologic evidence of human papillomavirus infection: a population-based case-control study. Cancer Epidemiol Biomarkers Prev, 12, 872-5.
- Afshar RM, Mollaie HR, Fazlalipour M, et al (2013). Prevalence and type distribution of human papillomavirus infection using the INNo-Lipa assay, Kerman, Southeast Iran. Asian Pac J Cancer Prev, 14, 5287-91. https://doi.org/10.7314/APJCP.2013.14.9.5287
- Agorastos T, Lambropoulos AF, Sotiriadis A, et al (2009). Prevalence and distribution of high-risk human papillomavirus in Greece. Eur J Cancer Prev, 18, 504-9. https://doi.org/10.1097/CEJ.0b013e32832abd5e
- Alemany L, Saunier M, Alvarado-Cabrero I, et al (2015). Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer, 136, 98-107. https://doi.org/10.1002/ijc.28963
- Anastos K, Hoover DR, Burk RD, et al (2010). Risk factors for cervical precancer and cancer in HIV-infected, HPV-positive Rwandan women. PLoS One, 5, 13525. https://doi.org/10.1371/journal.pone.0013525
- Antonsson A, Cornford M, Perry S, et al (2014). Prevalence and risk factors for oral HPV infection in young Australians. PLoS One, 9, 91761. https://doi.org/10.1371/journal.pone.0091761
- Barzi A, Klein EA, Dorff TB, et al (2015). Prostatectomy at high-volume centers improves outcomes and lowers the costs of care for prostate cancer. Prostate Cancer Prostatic Dis.
- Boccalini S, Tiscione E, Bechini A, et al (2012). Sexual behavior, use of contraceptive methods and risk factors for HPV infections of students living in central Italy: implications for vaccination strategies. J Prev Med Hyg, 53, 24-9.
- Bosnjak Z, Peric M, Krizan IR, et al (2013). Prevalence and genotype distribution of high-risk human papillomavirus (HR HPV) in male genital samples of Osijek-Baranja County. Coll Antropol, 37, 1203-8.
- Brody H (2015). Prostate cancer. Nature, 528, S117. https://doi.org/10.1038/528S117a
- Carozzi F, De Marco L, Gillio-Tos A, et al (2014). Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence. J Clin Virol, 60, 257-63. https://doi.org/10.1016/j.jcv.2014.04.009
- Carroll PR, Parsons JK, Andriole G, et al (2015). Prostate Cancer Early Detection, Version 2.2015. J Natl Compr Canc Netw, 13, 1534-61. https://doi.org/10.6004/jnccn.2015.0181
- Chelimo C, Wouldes TA, Cameron LD, et al (2013). Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer. J Infect, 66, 207-17. https://doi.org/10.1016/j.jinf.2012.10.024
- Damay A, Fabre J, Costes V, et al (2010). Human papillomavirus (HPV) prevalence and type distribution, and HPV-associated cytological abnormalities in anal specimens from men infected with HIV who have sex with men. J Med Virol, 82, 592-6. https://doi.org/10.1002/jmv.21732
- de Sanjose S, Diaz M, Castellsague X, et al (2007). Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis, 7, 453-9. https://doi.org/10.1016/S1473-3099(07)70158-5
- Denny L, Adewole I, Anorlu R, et al (2014). Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa. Int J Cancer, 134, 1389-98. https://doi.org/10.1002/ijc.28425
- Iftner T, Eberle S, Iftner A, et al (2010). Prevalence of low-risk and high-risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age: an epidemiological observational study. J Med Virol, 82, 1928-39. https://doi.org/10.1002/jmv.21910
- Kuczyk M, Serth J, Machtens S, et al (2000). Detection of viral HPV 16 DNA in prostate cancer and benign prostatic hyperplasia by quantitative PCR-directed analysis. Prostate Cancer Prostatic Dis, 3, 23. https://doi.org/10.1038/sj.pcan.4500448
- Lupi S, Bergamini M, Guidi E, et al (2014). Cross-sectional seroprevalence of antibodies against 6, 11, 16 and 18 human papillomavirus (HPV) types among teenagers and young women in Italy. Ann Ist Super Sanita, 50, 171-7.
- Martins AE, Lucena-Silva N, Garcia RG, et al (2014). Prevalence of human papillomavirus infection, distribution of viral types and risk factors in cervical samples from human immunodeficiency virus-positive women attending three human immunodeficiency virus-acquired immune deficiency syndrome reference centres in northeastern Brazil. Mem Inst Oswaldo Cruz, 0, 0.
- Michopoulou V, Derdas SP, Symvoulakis E, et al (2014). Detection of human papillomavirus (HPV) DNA prevalence and p53 codon 72 (Arg72Pro) polymorphism in prostate cancer in a Greek group of patients. Tumour Biol, 35, 12765-73. https://doi.org/10.1007/s13277-014-2604-7
- Niclis C, Pou SA, Bengio RH, et al (2011). Prostate cancer mortality trends in Argentina 1986-2006: an age-periodcohort and joinpoint analysis. Cad Saude Publica, 27, 123-30. https://doi.org/10.1590/S0102-311X2011000100013
- Orlando G, Fasolo M, Mazza F, et al (2014). Risk of cervical HPV infection and prevalence of vaccine-type and other high-risk HPV types among sexually active teens and young women (13-26 years) enrolled in the VALHIDATE study. Hum Vaccin Immunother, 10, 986-94. https://doi.org/10.4161/hv.27682
- Pierce Campbell CM, Messina JL, Stoler MH, et al (2013). Cutaneous human papillomavirus types detected on the surface of male external genital lesions: a case series within the HPV Infection in Men Study. J Clin Virol, 58, 652-9. https://doi.org/10.1016/j.jcv.2013.10.011
- Pourmand G, Salem S, Mehrsai A, et al (2007). The risk factors of prostate cancer: a multicentric case-control study in Iran. Asian Pac J Cancer Prev, 8, 422-8.
- Printz C (2015). FDA approves Gardasil 9 for more types of HPV. Cancer, 121, 1156-7. https://doi.org/10.1002/cncr.29374
- Reza MA, Fahimeh G, Reza MH (2012). Evaluation of xenotropic murine leukemia virus and its R426Q polymorphism in patients with prostate cancer in Kerman, southeast of Iran. Asian Pac J Cancer Prev, 13, 3669-73. https://doi.org/10.7314/APJCP.2012.13.8.3669
- Rosenblatt KA, Carter JJ, Iwasaki LM, et al (2003). Serologic evidence of human papillomavirus 16 and 18 infections and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 12, 763-8.
- Rotola A, Monini P, Di Luca D, et al (1992). Presence and physical state of HPV DNA in prostate and urinary-tract tissues. Int J Cancer, 52, 359-65. https://doi.org/10.1002/ijc.2910520306
- Sadjadi A, Nooraie M, Ghorbani A, et al (2007). The incidence of prostate cancer in Iran: results of a population-based cancer registry. Arch Iran Med, 10, 481-5.
- Safarinejad MR (2006). Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Iran. Ann Oncol, 17, 1166-71. https://doi.org/10.1093/annonc/mdl087
- Samsonov RB, Klochkova TG, Evtushenko VI (2012). [Infection of the prostate by herpesviruses and HPV in patients with prostate cancer]. Vopr Onkol, 58, 795-9.
- Stephanie P, Brandel F, Caitlin K, et al (2002). Prostate Cancer, Nutrition, and Dietary Supplements (PDQ (R)): Patient Version. In 'PDQ Cancer Information Summaries', Eds Bethesda (MD), J Clin Oncol, 20, 145-6
- Stolten M, Ledet E, Dotiwala A, et al (2015). Alternative Digit Ratios and Their Relationship to Prostate Cancer. Clin Genitourin Cancer, 14, 149-52
- Vinodhini K, Shanmughapriya S, Das BC, et al (2012). Prevalence and risk factors of HPV infection among women from various provinces of the world. Arch Gynecol Obstet, 285, 771-7. https://doi.org/10.1007/s00404-011-2155-8
- Walczak L, Dutkiewicz S, Marszalek A (2013). Incidence and prevalence of multiple types of genital human papillomavirus (HPV) infection in men: a study in Poland. Ginekol Pol, 84, 112-5.